María Argüello-Marina, Marta Callejas-Charavía, Beatriz Merchán-Muñoz, Daniel Gainza-Miranda, Agustina Rico-Zampetti, Raquel Pérez-Maganto, Gustavo Ruiz-Ares, Patricia García-Ramírez, Dunia de Miguel-Llorente, and Julio García-Suárez
Abstract Introduction This prospective multicentre study evaluates the impact of Palliative Care Unit (PCU) intervention (Experimental Group, EG), during autologous hematopoietic stem cell transplantation (AHSCT) on quality of life (QoL), symptom control and healthcare resource use compared to standard practice (Control Group, CG). We used validated scales on Days 0 (stem cell infusion), + 7 (bone marrow aplasia, acute symptoms) and + 21 (aplasia recovery). Results In 40 patients (20 EG/ 20 CG: 45%/25% female, median age 57.5/59), QoL differed significantly at Day + 7 (EG: median 0.50; CG: -63.00; p